Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.09 (market cap $44.49B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 22× GeneDx Holdings Corp's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and GeneDx Holdings Corp for 19 Days on average.
| JEPQ | WGS | |
|---|---|---|
Market Cap | $44.49B | $2.02B |
Volume | 5,681,789 | 734,640 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $167.51 |
52-Week Low | $53.77 | $34.51 |
Typical Hold Time | 66 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.09, down 0.29% on the day, with a bullish technical signal driven by moving averages. The ETF maintains strong income generation through its covered-call strategy, with recent monthly dividends ranging from $0.57 to $0.70. Technical analysis shows support at $60-61 and resistance at $61-62, while oscillators remain neutral with RSI at 47.13.
JEPQ offers high monthly income potential with an estimated 11% yield, though its covered-call strategy limits upside appreciation. The ETF provides exposure to Nasdaq technology stocks with downside protection during volatility. Key risks include market correlation, income variability, and competition from other income ETFs. Institutional interest remains strong, with Envestnet recently increasing its position.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
